Recruitment status changed
Before: Not yet recruiting. After: Recruiting.
Study sponsor: Viking Therapeutics, Inc. · VKTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: Not yet recruiting. After: Recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.